NCT01531283

Deacylated Ghrelin and Beta Cell Function

Impact of Unacylated Ghrelin on Beta-cell Function in Humans

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: David Dalessio · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

Use of human unacylated ghrelin (UAG, also called des-octanoyl ghrelin) to study physiology in healthy subjects. The proposed research is an investigator-initiated study funded by the National Institutes of Health designed to examine the effect of physiologic levels of UAG on the regulation of glucose homeostasis as well as beta cell function.

Conditions

• the Diabetic Process

Interventions

Type	Name	Description
DRUG	unacylated ghrelin	IV, UAG (4.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)
DRUG	acyl ghrelin	IV, AG (1.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)
DRUG	combined acyl and desacyl ghrelin	IV, the combination of AG (1 µg/kg/hr) and UAG (4 µg/kg/hr), one time, for the duration of the study visit (approximately 5 hours)
DRUG	saline	IV, saline, one time, for the duration of the study visit(approximately 5 hours)

Timeline

• Start date: 2011-02-01
• Primary completion: 2013-04-01
• First posted: 2012-02-10
• Last updated: 2012-11-14

Locations

1 site across 1 country: United States